N@N

SIMCERE PHARMACEUTICAL-ADR (NYSE:SCR), Up By 11.22% ($1.02) After BUYINS.NET SqueezeTrigger Report Released on Monday, January

^{Published on 2012-01-31 07:42:14 - WOPRAI}
 

January 31, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, released a report on Monday, January 9th 2012 at 09:15:00 PST stating that SIMCERE PHARMACEUTICAL-ADR (NYSE:SCR) was expected to be Up After it crossed above its SqueezeTrigger Price of 9.06 on Monday, January 9th 2012. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=scr&id=229051

From August 2009 to December 2011, an aggregate amount of 10802642 shares of SCR have been shorted for a total dollar value of $97223778. The SCR SqueezeTrigger price of $9.06 is the volume weighted average price that all shorts are short in shares of SCR. There is still approximately $1,690,816 of potential short covering in shares of SCR.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .

SIMCERE PHARMACEUTICAL-ADR (NYSE:SCR) - Simcere Pharmaceutical Group develops, manufactures, and markets branded generic pharmaceuticals in the Peoples Republic of China. The companys principal branded generic pharmaceuticals include edaravone injection pharmaceutical to treat strokes under the Bicun and Yidasheng brands; amoxicillin capsules, dispersible tablets, granules, and injection under the Zailin brand; generic diclofenac sodium, an anti-inflammatory pain reliever under the Yingtaiqing brand; and sustained release implants for cancer under the Sinofuan brand. Its other branded generic pharmaceutical products comprise generic OTC anti-diarrhea pharmaceuticals under the Biqi brand; amoxicillin and clavulanate potassium tablets, granules, and injection to treat infections under the Anqi brand; cefaclor in dry suspension antibiotics for infections under the Zaike brand; and OTC herbal medicines for coughs under the Simcere Kechuanning brand name. The company also offers pharmaceuticals under various brands in the areas of antibacterial and antiviral, anti-cancer, anti-allergic, anti-osteoporosis, cardiovascular and cerebrovascular, digestive conditions, anti-inflammatory, respiratory system, urinary conditions, and vaccines. As of March 31, 2010, it had 12 product candidates in various stages of development, including treatments for cancer, cerebrovascular diseases, infections, rheumatoid arthritis, nausea, and vomiting associated with chemotherapy. The company manufactures and sells 46 pharmaceuticals and distributes 2 pharmaceuticals that are manufactured by independent third parties under its brand names. It has agreements with Epitomics, Inc. to co-develop and produce humanized RabMAb antibody therapeutics for tumors; and Advenchen to research and develop anti-cancer pharmaceuticals. The company has strategic partnerships with Sun Yat-Sen University Cancer Center and Bristol-Myers Squibb. Simcere Pharmaceutical was founded in 1995 and is headquartered in Nanjing, the Peoples Republic of China.

The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net